PhorMed, Inc., a clinical stage biopharmaceutical company founded in 2019, is developing a drug internally called RP-323 or 12-O-tetradecanoylphorbol-13-acetate (TPA) aka phorbol-12-myristate-13-acetate (PMA).
PhorMed focuses on the development of human therapeutics that function at the cellular level, a cell repair therapy that targets along multiple cell lines, and fortunately these targets are important for the pathogenesis of several diseases, allowing it to become a Platform Technology. Our area of study covers Oncology/Hematology, Neurology and Anti-Inflammatory.
The company’s goal is to become first-line treatments for the disease states we are studying and potentially be a new drug class for Anti-Inflammation and Neurology.
RP-323 is a molecule derived from the oil of the Croton tiglium L. plant, a leafy shrub native to Southeast Asia. RP-323 is now synthesized.
Five indications are presently in the pipeline and the company will continue to expand through it’s continued dedication in research and development We are committed to the highest standards of scientific excellence and integrity to accomplish these goals for our patients and society.
Healthy cells proliferate (grow), differentiate (specialize), and undergo apoptosis, or programmed cell death, a natural process that is as important to a healthy cell cycle as proliferation. For instance, fingers and toes in a human embryo occur because the cells between the fingers ‘apoptose,’ resulting in separated digits.
In disease states, such as cancer or neurological disorders, this natural cell cycle is disrupted. Either not enough new healthy cells are made, or these new cells keep diving and growing forever, overwhelming the body’s natural cycles, crowding out healthy tissue, causing such disease states as tumors, leukemia, and cytokine storms:
All these disease states are caused by errors in gene expression. This is where RP-323 comes in.